Heritable methylation marks associated with prostate cancer risk

James G. Dowty; Chenglong Yu; Mahnaz Hosseinpour; Jihoon Eric Joo; Ee Ming Wong; Tu Nguyen-Dumont; Joseph Rosenbluh; Graham G. Giles; Roger L. Milne; Robert J. MacInnis; Pierre Antoine Dugué; Melissa C. Southey

doi:10.1007/s10689-022-00325-w

Heritable methylation marks associated with prostate cancer risk

James G. Dowty
, Chenglong Yu
, Mahnaz Hosseinpour
, Jihoon Eric Joo
, Ee Ming Wong
, Tu Nguyen-Dumont
, Joseph Rosenbluh
, Graham G. Giles
, Roger L. Milne
, Robert J. MacInnis
, Pierre Antoine Dugué
, Melissa C. Southey

Research output: Contribution to journal › Article › Research › peer-review

6 Citations (Scopus)

Abstract

DNA methylation marks that are inherited from parents to offspring are known to play a role in cancer risk and could explain part of the familial risk for cancer. We therefore conducted a genome-wide search for heritable methylation marks associated with prostate cancer risk. Peripheral blood DNA methylation was measured for 133 of the 469 members of 25 multiple-case prostate cancer families, using the EPIC array. We used these families to systematically search the genome for methylation marks with Mendelian patterns of inheritance, then we tested the 1,000 most heritable marks for association with prostate cancer risk. After correcting for multiple testing, 41 heritable methylation marks were associated with prostate cancer risk. Separate analyses, based on 869 incident cases and 869 controls from a prospective cohort study, showed that 9 of these marks near the metastable epiallele VTRNA2-1 were also nominally associated with aggressive prostate cancer risk in the population.

Original language	English
Pages (from-to)	313-317
Number of pages	5
Journal	Familial Cancer
Volume	22
Issue number	3
DOIs	https://doi.org/10.1007/s10689-022-00325-w
Publication status	Published - Jul 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Aggressive prostate cancer
DNA methylation
Familial prostate cancer
Heritable methylation marks
Prostate cancer risk
Trans-generational inheritance

Access to Document

10.1007/s10689-022-00325-wLicence: CC BY

Cite this

@article{598c1aa7e4364cc68b567c957a8583da,

title = "Heritable methylation marks associated with prostate cancer risk",

abstract = "DNA methylation marks that are inherited from parents to offspring are known to play a role in cancer risk and could explain part of the familial risk for cancer. We therefore conducted a genome-wide search for heritable methylation marks associated with prostate cancer risk. Peripheral blood DNA methylation was measured for 133 of the 469 members of 25 multiple-case prostate cancer families, using the EPIC array. We used these families to systematically search the genome for methylation marks with Mendelian patterns of inheritance, then we tested the 1,000 most heritable marks for association with prostate cancer risk. After correcting for multiple testing, 41 heritable methylation marks were associated with prostate cancer risk. Separate analyses, based on 869 incident cases and 869 controls from a prospective cohort study, showed that 9 of these marks near the metastable epiallele VTRNA2-1 were also nominally associated with aggressive prostate cancer risk in the population.",

keywords = "Aggressive prostate cancer, DNA methylation, Familial prostate cancer, Heritable methylation marks, Prostate cancer risk, Trans-generational inheritance",

author = "Dowty, \{James G.\} and Chenglong Yu and Mahnaz Hosseinpour and Joo, \{Jihoon Eric\} and Wong, \{Ee Ming\} and Tu Nguyen-Dumont and Joseph Rosenbluh and Giles, \{Graham G.\} and Milne, \{Roger L.\} and MacInnis, \{Robert J.\} and Dugu{\'e}, \{Pierre Antoine\} and Southey, \{Melissa C.\}",

note = "Funding Information: This work was funded by a Novel Concept Award from the Prostate Cancer Foundation of Australia (Southey, NCG-0716). MCS is a Senior Research Fellow of the National Health and Medical Research Council of Australia (GNT1155163). The MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further augmented by Australian National Health and Medical Research Council grants 209057, 251553, 504711, 396414, 1074383, and by infrastructure provided by Cancer Council Victoria. The MCCS methylation studies were supported by the NHMRC grants 1011618, 1026892, 1027505, 1050198, 1043616, 1074383 and 1164455. TN-D is a National Breast Cancer Foundation (Australia) Career Development Fellow (ECF-17-001). The Australian Prostate Cancer Family Study was supported by National Health and Medical Research Council grant 930494, Tattersall{\textquoteright}s, The Whitten Foundation, and by infrastructure provided by Cancer Council Victoria. Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = jul,

doi = "10.1007/s10689-022-00325-w",

language = "English",

volume = "22",

pages = "313--317",

journal = "Familial Cancer",

issn = "1389-9600",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - Heritable methylation marks associated with prostate cancer risk

AU - Dowty, James G.

AU - Yu, Chenglong

AU - Hosseinpour, Mahnaz

AU - Joo, Jihoon Eric

AU - Wong, Ee Ming

AU - Nguyen-Dumont, Tu

AU - Rosenbluh, Joseph

AU - Giles, Graham G.

AU - Milne, Roger L.

AU - MacInnis, Robert J.

AU - Dugué, Pierre Antoine

AU - Southey, Melissa C.

N1 - Funding Information: This work was funded by a Novel Concept Award from the Prostate Cancer Foundation of Australia (Southey, NCG-0716). MCS is a Senior Research Fellow of the National Health and Medical Research Council of Australia (GNT1155163). The MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further augmented by Australian National Health and Medical Research Council grants 209057, 251553, 504711, 396414, 1074383, and by infrastructure provided by Cancer Council Victoria. The MCCS methylation studies were supported by the NHMRC grants 1011618, 1026892, 1027505, 1050198, 1043616, 1074383 and 1164455. TN-D is a National Breast Cancer Foundation (Australia) Career Development Fellow (ECF-17-001). The Australian Prostate Cancer Family Study was supported by National Health and Medical Research Council grant 930494, Tattersall’s, The Whitten Foundation, and by infrastructure provided by Cancer Council Victoria. Publisher Copyright: © 2023, The Author(s).

PY - 2023/7

Y1 - 2023/7

N2 - DNA methylation marks that are inherited from parents to offspring are known to play a role in cancer risk and could explain part of the familial risk for cancer. We therefore conducted a genome-wide search for heritable methylation marks associated with prostate cancer risk. Peripheral blood DNA methylation was measured for 133 of the 469 members of 25 multiple-case prostate cancer families, using the EPIC array. We used these families to systematically search the genome for methylation marks with Mendelian patterns of inheritance, then we tested the 1,000 most heritable marks for association with prostate cancer risk. After correcting for multiple testing, 41 heritable methylation marks were associated with prostate cancer risk. Separate analyses, based on 869 incident cases and 869 controls from a prospective cohort study, showed that 9 of these marks near the metastable epiallele VTRNA2-1 were also nominally associated with aggressive prostate cancer risk in the population.

AB - DNA methylation marks that are inherited from parents to offspring are known to play a role in cancer risk and could explain part of the familial risk for cancer. We therefore conducted a genome-wide search for heritable methylation marks associated with prostate cancer risk. Peripheral blood DNA methylation was measured for 133 of the 469 members of 25 multiple-case prostate cancer families, using the EPIC array. We used these families to systematically search the genome for methylation marks with Mendelian patterns of inheritance, then we tested the 1,000 most heritable marks for association with prostate cancer risk. After correcting for multiple testing, 41 heritable methylation marks were associated with prostate cancer risk. Separate analyses, based on 869 incident cases and 869 controls from a prospective cohort study, showed that 9 of these marks near the metastable epiallele VTRNA2-1 were also nominally associated with aggressive prostate cancer risk in the population.

KW - Aggressive prostate cancer

KW - DNA methylation

KW - Familial prostate cancer

KW - Heritable methylation marks

KW - Prostate cancer risk

KW - Trans-generational inheritance

UR - https://www.scopus.com/pages/publications/85146956117

U2 - 10.1007/s10689-022-00325-w

DO - 10.1007/s10689-022-00325-w

M3 - Article

C2 - 36708485

AN - SCOPUS:85146956117

SN - 1389-9600

VL - 22

SP - 313

EP - 317

JO - Familial Cancer

JF - Familial Cancer

IS - 3

ER -

Heritable methylation marks associated with prostate cancer risk

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Precision Medicine for Prostate and Breast Cancer

Increasing precision in epidemiological exposure assessment by integrating genetic and epigenetic data

Precision Public Health for major cancers - novel approaches to building the genetic, epigenetic and lifestyle knowledge base for assessing risk and prognosis

Cite this

Heritable methylation marks associated with prostate cancer risk

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Projects

Precision Medicine for Prostate and Breast Cancer

Increasing precision in epidemiological exposure assessment by integrating genetic and epigenetic data

Precision Public Health for major cancers - novel approaches to building the genetic, epigenetic and lifestyle knowledge base for assessing risk and prognosis

Cite this